Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
161.9M
Short interest
settlement 2026-10-15
4.4
Days to cover
-1.7 days vs prior
45.8%
Short share of volume
2026-10-28
490,129
Fails to deliver
settlement 2026-09-30
Wed 24 Feb
Next earnings
estimated date
-$644K
Insider flow, 90 days
0 buys, 5 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in RXRX is 161,926,247 shares, down 16,798,186 shares over the last month. Over the last 48 readings it ranged from 62,427,631 shares (31 October 2024) to 184,440,829 shares (15 May 2026). At the reported average volume of 36.5M shares a day that is 4.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rxrx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 161,926,247 | +2.5% | 36,463,213 | 4.44 |
| 2026-09-30 | 157,938,412 | -11.6% | 25,774,840 | 6.13 |
| 2026-09-15 | 178,724,433 | -0.2% | 14,224,300 | 12.56 |
| 2026-08-31 | 179,145,796 | +0.7% | 16,898,236 | 10.60 |
| 2026-08-14 | 177,923,359 | -1.6% | 13,306,552 | 13.37 |
| 2026-07-31 | 180,771,459 | +0.0% | 19,411,865 | 9.31 |
| 2026-07-15 | 180,760,541 | +4.9% | 26,882,189 | 6.72 |
| 2026-06-30 | 172,302,180 | -6.4% | 20,547,113 | 8.39 |
| 2026-06-15 | 184,017,785 | +12.0% | 22,006,664 | 8.36 |
| 2026-05-29 | 164,340,230 | -10.9% | 20,501,178 | 8.02 |
| 2026-05-15 | 184,440,829 | +7.7% | 13,889,498 | 13.28 |
| 2026-04-30 | 171,321,811 | -1.8% | 11,590,459 | 14.78 |
| 2026-04-15 | 174,397,876 | +0.3% | 10,187,971 | 17.12 |
| 2026-03-31 | 173,926,845 | -0.1% | 14,147,466 | 12.29 |
| 2026-03-13 | 174,136,749 | +3.3% | 13,739,894 | 12.67 |
| 2026-02-27 | 168,516,142 | -2.7% | 19,015,637 | 8.86 |
| 2026-02-13 | 173,170,498 | +4.6% | 22,708,637 | 7.63 |
| 2026-01-30 | 165,548,707 | +1.3% | 20,828,750 | 7.95 |
| 2026-01-15 | 163,381,460 | -1.4% | 20,049,755 | 8.15 |
| 2025-12-31 | 165,731,774 | +7.8% | 26,991,184 | 6.14 |
| 2025-12-15 | 153,738,758 | +1.2% | 18,710,464 | 8.22 |
| 2025-11-28 | 151,875,532 | +4.3% | 23,432,154 | 6.48 |
| 2025-11-14 | 145,661,814 | +13.3% | 37,489,816 | 3.89 |
| 2025-10-31 | 128,586,047 | +1.8% | 64,709,381 | 1.99 |
| 2025-10-15 | 126,348,417 | -5.3% | 69,403,970 | 1.82 |
| 2025-09-30 | 133,407,394 | +1.0% | 35,928,102 | 3.71 |
| 2025-09-15 | 132,044,177 | +6.4% | 16,730,338 | 7.89 |
| 2025-08-29 | 124,079,106 | +1.5% | 16,288,078 | 7.62 |
| 2025-08-15 | 122,223,405 | +4.0% | 18,598,548 | 6.57 |
| 2025-07-31 | 117,535,748 | +1.7% | 33,007,194 | 3.56 |
| 2025-07-15 | 115,527,481 | -1.6% | 30,617,579 | 3.77 |
| 2025-06-30 | 117,408,745 | -2.2% | 27,422,295 | 4.28 |
| 2025-06-13 | 120,075,634 | +10.1% | 36,749,679 | 3.27 |
| 2025-05-30 | 109,034,492 | +4.6% | 19,542,619 | 5.58 |
| 2025-05-15 | 104,219,046 | +11.9% | 22,023,595 | 4.73 |
| 2025-04-30 | 93,117,686 | -1.5% | 14,415,360 | 6.46 |
| 2025-04-15 | 94,515,655 | +6.8% | 30,201,892 | 3.13 |
| 2025-03-31 | 88,501,554 | +2.4% | 15,553,625 | 5.69 |
| 2025-03-14 | 86,416,564 | +7.1% | 20,466,609 | 4.22 |
| 2025-02-28 | 80,716,710 | +7.0% | 37,222,808 | 2.17 |
| 2025-02-14 | 75,450,107 | +18.4% | 33,427,821 | 2.26 |
| 2025-01-31 | 63,748,978 | -6.1% | 17,727,159 | 3.60 |
| 2025-01-15 | 67,857,806 | -8.0% | 15,986,169 | 4.24 |
| 2024-12-31 | 73,735,739 | +9.9% | 16,275,526 | 4.53 |
| 2024-12-13 | 67,097,533 | -1.1% | 17,100,772 | 3.92 |
| 2024-11-29 | 67,845,763 | +5.1% | 12,760,225 | 5.32 |
| 2024-11-15 | 64,573,303 | +3.4% | 6,991,077 | 9.24 |
| 2024-10-31 | 62,427,631 | +5.0% | 3,799,526 | 16.43 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of RXRX volume is 45.8%, down 0.5 points over the last five sessions. Over the last 30 readings it ranged from 33.4% (27 October 2026) to 66.3% (2 October 2026). The latest reading is 7.3 points below the 30-session average of 53.2%, on 14.1M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 6.5M | 14.1M | 45.8% | 22,018 |
| 2026-10-27 | 3.9M | 11.6M | 33.4% | 6,554 |
| 2026-10-26 | 4.6M | 8.8M | 52.0% | 54,163 |
| 2026-10-23 | 5.0M | 9.8M | 50.9% | 65,755 |
| 2026-10-22 | 4.9M | 10.1M | 48.6% | 4,007 |
| 2026-10-21 | 4.7M | 10.0M | 46.4% | 29,525 |
| 2026-10-20 | 5.6M | 9.7M | 58.4% | 36,803 |
| 2026-10-19 | 6.4M | 11.1M | 57.5% | 849,078 |
| 2026-10-16 | 11.4M | 21.7M | 52.2% | 811,778 |
| 2026-10-15 | 15.5M | 30.9M | 50.1% | 20,531 |
| 2026-10-14 | 4.3M | 9.7M | 44.5% | 7,334 |
| 2026-10-13 | 6.3M | 10.8M | 58.2% | 825,558 |
| 2026-10-12 | 7.7M | 13.7M | 56.0% | 279,828 |
| 2026-10-09 | 8.5M | 19.6M | 43.5% | 1,446,301 |
| 2026-10-08 | 7.5M | 14.8M | 51.1% | 490,209 |
| 2026-10-07 | 14.8M | 24.1M | 61.5% | 68,280 |
| 2026-10-06 | 20.8M | 35.5M | 58.8% | 114,471 |
| 2026-10-05 | 20.0M | 34.1M | 58.7% | 32,505 |
| 2026-10-02 | 6.5M | 9.7M | 66.3% | 16,703 |
| 2026-10-01 | 4.2M | 8.0M | 53.2% | 17,242 |
| 2026-09-30 | 9.1M | 15.7M | 58.2% | 74,865 |
| 2026-09-29 | 6.2M | 11.9M | 52.1% | 3,041 |
| 2026-09-28 | 2.9M | 5.9M | 48.9% | 2,929 |
| 2026-09-25 | 3.0M | 5.0M | 59.6% | 255 |
| 2026-09-24 | 5.1M | 8.9M | 57.8% | 3,158 |
| 2026-09-23 | 7.8M | 13.0M | 60.1% | 33,009 |
| 2026-09-22 | 9.6M | 19.3M | 50.0% | 14,235 |
| 2026-09-21 | 8.7M | 15.6M | 55.9% | 44,449 |
| 2026-09-18 | 6.6M | 10.9M | 60.6% | 8,434 |
| 2026-09-17 | 6.5M | 14.4M | 45.4% | 40,859 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in RXRX is 490,129 shares, down 137,296 shares over the last settlement date. Over the last 30 readings it ranged from 6 shares (11 August 2026) to 2,726,286 shares (21 September 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 490,129 | $4.03 | $2.0M |
| 2026-09-29 | 627,425 | $3.70 | $2.3M |
| 2026-09-28 | 782,942 | $3.74 | $2.9M |
| 2026-09-25 | 470,126 | $3.89 | $1.8M |
| 2026-09-24 | 242,524 | $3.70 | $897K |
| 2026-09-23 | 73,931 | $4.05 | $299K |
| 2026-09-22 | 6,329 | $3.97 | $25K |
| 2026-09-21 | 2,726,286 | $3.83 | $10.4M |
| 2026-09-18 | 9,853 | $3.54 | $35K |
| 2026-09-17 | 1,996,570 | $3.19 | $6.4M |
| 2026-09-14 | 497,478 | $3.20 | $1.6M |
| 2026-09-10 | 400,138 | $3.22 | $1.3M |
| 2026-09-09 | 72,869 | $3.44 | $251K |
| 2026-09-08 | 1,917 | $3.63 | $7K |
| 2026-09-04 | 73 | $3.44 | $251 |
| 2026-09-03 | 247,538 | $3.38 | $837K |
| 2026-09-01 | 189,092 | $3.40 | $643K |
| 2026-08-31 | 345,423 | $3.34 | $1.2M |
| 2026-08-28 | 4,021 | $3.44 | $14K |
| 2026-08-26 | 302,205 | $3.56 | $1.1M |
| 2026-08-25 | 124,054 | $3.25 | $403K |
| 2026-08-24 | 135,512 | $3.50 | $474K |
| 2026-08-20 | 190,339 | $3.50 | $666K |
| 2026-08-19 | 315,374 | $3.09 | $975K |
| 2026-08-18 | 5,663 | $3.11 | $18K |
| 2026-08-17 | 107,727 | $3.16 | $340K |
| 2026-08-14 | 37,071 | $3.31 | $123K |
| 2026-08-12 | 4,705 | $3.35 | $16K |
| 2026-08-11 | 6 | $3.29 | $20 |
| 2026-08-10 | 7,517 | $3.22 | $24K |
Insider trades
SEC Form 4, newest first. JSONInsiders at RXRX reported 5 open-market sells worth $644K in the last 90 days and no open-market buys. Latest filing: HERSHBERG ROBERT (Director) on 2026-10-06.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | HERSHBERG ROBERT | Director | Sell | 25K | $5.00 | $125K | 162K |
| 2026-10-06 | HERSHBERG ROBERT | Director | Exercise or conversion | 25K | $2.22 | $56K | 187K |
| 2026-10-06 | Borgeson Blake | Director | Sell | 50K | $4.84 | $242K | 6.1M |
| 2026-10-01 | Li Dean Y | Director | Grant | 3K | $0.00 | $0 | 1.5M |
| 2026-10-01 | Dar Zavain | Director | Grant | 5K | $0.00 | $0 | 245K |
| 2026-09-15 | Taylor Ben R | Chief Financial Officer | Tax withholding | 5K | $3.41 | $18K | 1.1M |
| 2026-09-08 | Khan Najat | CEO and President | Sell | 22K | $3.52 | $79K | 2.1M |
| 2026-09-01 | Borgeson Blake | Director | Sell | 30K | $3.34 | $100K | 6.2M |
| 2026-08-17 | Taylor Ben R | Chief Financial Officer | Tax withholding | 25K | $3.16 | $79K | 1.1M |
| 2026-08-17 | Khan Najat | CEO and President | Tax withholding | 80K | $3.16 | $254K | 2.1M |
| 2026-08-17 | Hallett David | Chief Scientific Officer | Tax withholding | 27K | $3.16 | $84K | 1.0M |
| 2026-08-04 | Borgeson Blake | Director | Sell | 30K | $3.25 | $98K | 6.2M |
| 2026-07-07 | Borgeson Blake | Director | Sell | 40K | $3.96 | $159K | 6.2M |
| 2026-07-01 | Li Dean Y | Director | Grant | 4K | $0.00 | $0 | 1.5M |
| 2026-07-01 | Dar Zavain | Director | Grant | 5K | $0.00 | $0 | 241K |
| 2026-06-18 | Bumpus Namandje | Director | Sell | 4K | $3.18 | $13K | 128K |
| 2026-06-17 | Bumpus Namandje | Director | Grant | 88K | $0.00 | $0 | 132K |
| 2026-06-17 | Li Dean Y | Director | Grant | 88K | $0.00 | $0 | 1.5M |
| 2026-06-17 | Dar Zavain | Director | Grant | 88K | $0.00 | $0 | 236K |
| 2026-06-17 | Sun Elaine D | Director | Grant | 88K | $0.00 | $0 | 136K |
| 2026-06-17 | Michor Franziska | Director | Grant | 88K | $0.00 | $0 | 215K |
| 2026-06-17 | HERSHBERG ROBERT | Director | Grant | 88K | $0.00 | $0 | 162K |
| 2026-06-17 | Borgeson Blake | Director | Grant | 88K | $0.00 | $0 | 6.3M |
| 2026-06-15 | Taylor Ben R | Chief Financial Officer | Tax withholding | 5K | $3.15 | $17K | 1.1M |
| 2026-06-05 | Khan Najat | CEO and President | Sell | 24K | $3.58 | $84K | 2.2M |
| 2026-06-05 | Gibson Christopher | Director | Sell | 40K | $3.62 | $145K | 884K |
| 2026-06-05 | Gibson Christopher | Director | Conversion | 40K | $0.00 | $0 | 924K |
| 2026-06-03 | Bumpus Namandje | Director | Sell | 4K | $3.54 | $16K | 43K |
| 2026-06-02 | Borgeson Blake | Director | Sell | 30K | $3.68 | $110K | 6.2M |
| 2026-05-22 | Gibson Christopher | Director | Sell | 40K | $3.08 | $123K | 884K |
| 2026-05-22 | Gibson Christopher | Director | Conversion | 40K | $0.00 | $0 | 924K |
| 2026-05-15 | Taylor Ben R | Chief Financial Officer | Tax withholding | 25K | $3.04 | $76K | 1.1M |
| 2026-05-15 | Khan Najat | CEO and President | Tax withholding | 63K | $3.04 | $191K | 2.2M |
| 2026-05-15 | Hallett David | Chief Scientific Officer | Tax withholding | 27K | $3.04 | $81K | 1.1M |
| 2026-05-15 | Gibson Christopher | Director | Tax withholding | 23K | $3.04 | $69K | 884K |
| 2026-05-07 | Gibson Christopher | Director | Gift | 20K | $0.00 | $0 | 907K |
| 2026-05-07 | Gibson Christopher | Director | Sell | 40K | $3.37 | $135K | 927K |
| 2026-05-07 | Gibson Christopher | Director | Conversion | 60K | $0.00 | $0 | 967K |
| 2026-05-05 | Borgeson Blake | Director | Sell | 30K | $3.52 | $106K | 6.2M |
| 2026-04-22 | Gibson Christopher | Director | Sell | 40K | $3.61 | $144K | 907K |
| 2026-04-22 | Gibson Christopher | Director | Conversion | 40K | $0.00 | $0 | 947K |
| 2026-04-07 | Gibson Christopher | Director | Sell | 40K | $3.10 | $124K | 907K |
| 2026-04-07 | Gibson Christopher | Director | Conversion | 40K | $0.00 | $0 | 947K |
| 2026-04-07 | Borgeson Blake | Director | Sell | 30K | $3.10 | $93K | 6.2M |
| 2026-04-06 | Taylor Ben R | Chief Financial Officer | Tax withholding | 48K | $3.11 | $149K | 1.1M |
| 2026-04-01 | Li Dean Y | Director | Grant | 3K | $0.00 | $0 | 1.2M |
| 2026-04-01 | Dar Zavain | Director | Grant | 5K | $0.00 | $0 | 147K |
| 2026-03-23 | Gibson Christopher | Director | Sell | 40K | $3.25 | $130K | 907K |
| 2026-03-23 | Gibson Christopher | Director | Conversion | 40K | $0.00 | $0 | 947K |
| 2026-03-17 | Taylor Ben R | Chief Financial Officer | Sell | 8K | $3.39 | $27K | 1.2M |
| 2026-03-16 | Taylor Ben R | Chief Financial Officer | Tax withholding | 7K | $3.42 | $24K | 1.2M |
| 2026-03-09 | Khan Najat | CEO and President | Sell | 28K | $3.35 | $95K | 2.3M |
| 2026-03-09 | Gibson Christopher | Director | Gift | 20K | $0.00 | $0 | 907K |
| 2026-03-09 | Gibson Christopher | Director | Conversion | 20K | $0.00 | $0 | 927K |
| 2026-03-03 | Borgeson Blake | Director | Sell | 170K | $3.46 | $588K | 6.3M |
| 2026-02-19 | Gibson Christopher | Director | Sell | 40K | $3.46 | $138K | 907K |
| 2026-02-19 | Gibson Christopher | Director | Conversion | 40K | $0.00 | $0 | 947K |
| 2026-02-18 | Taylor Ben R | Chief Financial Officer | Sell | 13K | $3.08 | $41K | 1.2M |
| 2026-02-17 | Taylor Ben R | Chief Financial Officer | Tax withholding | 12K | $3.49 | $42K | 1.2M |
| 2026-02-17 | Khan Najat | CEO and President | Tax withholding | 14K | $3.49 | $50K | 2.3M |
| 2026-02-17 | Hallett David | Chief Scientific Officer | Tax withholding | 12K | $3.49 | $42K | 1.1M |
| 2026-02-17 | Gibson Christopher | Director | Tax withholding | 27K | $3.49 | $95K | 907K |
| 2026-02-06 | Gibson Christopher | Director | Tax withholding | 10K | $3.56 | $37K | 934K |
| 2026-02-06 | Gibson Christopher | Director | Grant | 30K | $0.00 | $0 | 944K |
| 2026-02-06 | Taylor Ben R | Chief Financial Officer | Tax withholding | 11K | $3.98 | $45K | 1.2M |
| 2026-02-06 | Taylor Ben R | Chief Financial Officer | Grant | 24K | $0.00 | $0 | 1.2M |
| 2026-02-06 | Taylor Ben R | Chief Financial Officer | Grant | 446K | $0.00 | $0 | 1.2M |
| 2026-02-06 | Khan Najat | CEO and President | Tax withholding | 10K | $3.98 | $41K | 2.3M |
| 2026-02-06 | Khan Najat | CEO and President | Grant | 30K | $0.00 | $0 | 2.3M |
| 2026-02-06 | Khan Najat | CEO and President | Grant | 1.7M | $0.00 | $0 | 2.3M |
| 2026-02-06 | Hallett David | Chief Scientific Officer | Tax withholding | 11K | $3.98 | $45K | 1.1M |
| 2026-02-06 | Hallett David | Chief Scientific Officer | Grant | 24K | $0.00 | $0 | 1.1M |
| 2026-02-06 | Hallett David | Chief Scientific Officer | Grant | 502K | $0.00 | $0 | 1.1M |
| 2026-02-04 | Gibson Christopher | Director | Sell | 40K | $4.12 | $165K | 914K |
| 2026-02-04 | Gibson Christopher | Director | Conversion | 40K | $0.00 | $0 | 954K |
| 2026-02-03 | Borgeson Blake | Director | Sell | 220K | $4.20 | $924K | 6.4M |
| 2026-01-20 | Gibson Christopher | Director | Sell | 40K | $4.47 | $179K | 914K |
| 2026-01-20 | Gibson Christopher | Director | Conversion | 40K | $0.00 | $0 | 954K |
| 2026-01-06 | Borgeson Blake | Director | Sell | 220K | $4.36 | $959K | 6.6M |
| 2026-01-05 | Gibson Christopher | Director | Gift | 20K | $0.00 | $0 | 914K |
| 2026-01-05 | Gibson Christopher | Director | Sell | 40K | $4.25 | $170K | 934K |
| 2026-01-05 | Gibson Christopher | Director | Conversion | 60K | $0.00 | $0 | 974K |
| 2026-01-02 | Li Dean Y | Director | Grant | 2K | $0.00 | $0 | 1.2M |
| 2026-01-02 | Dar Zavain | Director | Grant | 4K | $0.00 | $0 | 142K |
| 2025-12-29 | Taylor Ben R | Chief Financial Officer | Sell | 21K | $4.18 | $89K | 762K |
| 2025-12-22 | Khan Najat | Chief R&D Commercial Officer | Sell | 124K | $4.41 | $549K | 611K |
| 2025-12-19 | Gibson Christopher | Chief Executive Officer | Sell | 40K | $4.50 | $180K | 914K |
| 2025-12-19 | Gibson Christopher | Chief Executive Officer | Conversion | 40K | $0.00 | $0 | 954K |
| 2025-12-15 | Taylor Ben R | Chief Financial Officer | Tax withholding | 7K | $4.33 | $31K | 783K |
| 2025-12-04 | Gibson Christopher | Chief Executive Officer | Gift | 20K | $0.00 | $0 | 914K |
| 2025-12-04 | Gibson Christopher | Chief Executive Officer | Sell | 40K | $4.63 | $185K | 934K |
| 2025-12-04 | Gibson Christopher | Chief Executive Officer | Conversion | 60K | $0.00 | $0 | 974K |
| 2025-12-02 | Borgeson Blake | Director | Sell | 220K | $4.37 | $961K | 6.9M |
| 2025-11-25 | Taylor Ben R | Chief Financial Officer | Tax withholding | 2K | $4.03 | $9K | 790K |
| 2025-11-19 | Gibson Christopher | Chief Executive Officer | Sell | 40K | $4.16 | $166K | 914K |
| 2025-11-19 | Gibson Christopher | Chief Executive Officer | Conversion | 40K | $0.00 | $0 | 954K |
| 2025-11-17 | Taylor Ben R | Chief Financial Officer | Tax withholding | 12K | $4.14 | $49K | 792K |
| 2025-11-17 | Khan Najat | Chief R&D Commercial Officer | Tax withholding | 18K | $4.14 | $73K | 736K |
| 2025-11-17 | Gibson Christopher | Chief Executive Officer | Tax withholding | 40K | $4.14 | $167K | 914K |
| 2025-11-05 | Khan Najat | Chief R&D Commercial Officer | Grant | 85K | $0.00 | $0 | 753K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON50 Form 144 notices on file for RXRX worth $13.4M at the prices reported; 13 in the last 90 days worth $2.9M. Latest: Borgeson Blake filed on 2026-10-06 to sell 50,000 shares ($242K) from 2026-10-06.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-06 | Borgeson BlakeDirector | 50K | $242K | 0.009% | 2026-10-06 | Fidelity Brokerage Services LLC |
| 2026-10-06 | HERSHBERG ROBERTDirector | 25K | $125K | 0.005% | 2026-10-06 | Fidelity Brokerage Services LLC |
| 2026-09-01 | Borgeson BlakeDirector | 30K | $100K | 0.006% | 2026-09-01 | Fidelity Brokerage Services LLC |
| 2026-08-21 | Gibson ChristopherFormer Director | 77K | $262K | 0.014% | 2026-08-21 | Fidelity Brokerage Services LLC |
| 2026-08-20 | Gibson ChristopherFormer Director | 75K | $255K | 0.014% | 2026-08-20 | Fidelity Brokerage Services LLC |
| 2026-08-19 | Gibson ChristopherFormer Director | 100K | $328K | 0.019% | 2026-08-19 | Fidelity Brokerage Services LLC |
| 2026-08-18 | Gibson ChristopherFormer Director | 27K | $80K | 0.005% | 2026-08-18 | Fidelity Brokerage Services LLC |
| 2026-08-13 | Gibson ChristopherFormer Director | 100K | $331K | 0.019% | 2026-08-13 | Fidelity Brokerage Services LLC |
| 2026-08-12 | Gibson ChristopherFormer Director | 50K | $169K | 0.009% | 2026-08-12 | Fidelity Brokerage Services LLC |
| 2026-08-10 | Gibson ChristopherFormer Director | 100K | $327K | 0.019% | 2026-08-10 | Fidelity Brokerage Services LLC |
| 2026-08-07 | Gibson ChristopherFormer Director | 100K | $325K | 0.019% | 2026-08-07 | Fidelity Brokerage Services LLC |
| 2026-08-04 | Gibson ChristopherFormer Director | 75K | $245K | 0.014% | 2026-08-04 | Fidelity Brokerage Services LLC |
| 2026-08-04 | Borgeson BlakeDirector | 30K | $98K | 0.006% | 2026-08-04 | Fidelity Brokerage Services LLC |
| 2026-07-30 | Gibson ChristopherFormer Director | 75K | $225K | 0.014% | 2026-07-30 | Fidelity Brokerage Services LLC |
| 2026-07-29 | Gibson ChristopherFormer Director | 50K | $151K | 0.010% | 2026-07-29 | Fidelity Brokerage Services LLC |
| 2026-07-27 | Gibson ChristopherFormer Director | 50K | $153K | 0.010% | 2026-07-27 | Fidelity Brokerage Services LLC |
| 2026-07-21 | Gibson ChristopherFormer Director | 100K | $304K | 0.019% | 2026-07-21 | Fidelity Brokerage Services LLC |
| 2026-07-20 | Gibson ChristopherFormer Director | 100K | $290K | 0.019% | 2026-07-20 | Fidelity Brokerage Services LLC |
| 2026-07-17 | Gibson ChristopherFormer Director | 100K | $297K | 0.019% | 2026-07-17 | Fidelity Brokerage Services LLC |
| 2026-07-16 | Gibson ChristopherFormer Director | 100K | $311K | 0.019% | 2026-07-16 | Fidelity Brokerage Services LLC |
| 2026-07-15 | Gibson ChristopherFormer Director | 123K | $410K | 0.024% | 2026-07-15 | Fidelity Brokerage Services LLC |
| 2026-07-14 | Gibson ChristopherFormer Director | 100K | $330K | 0.019% | 2026-07-14 | Fidelity Brokerage Services LLC |
| 2026-07-13 | Gibson ChristopherFormer Director | 100K | $343K | 0.019% | 2026-07-13 | Fidelity Brokerage Services LLC |
| 2026-07-10 | Gibson ChristopherFormer Director | 100K | $354K | 0.019% | 2026-07-10 | Fidelity Brokerage Services LLC |
| 2026-07-09 | Gibson ChristopherFormer Director | 286K | $1.1M | 0.055% | 2026-07-09 | Fidelity Brokerage Services LLC |
| 2026-07-08 | Gibson ChristopherFormer Director | 200K | $738K | 0.038% | 2026-07-08 | Fidelity Brokerage Services LLC |
| 2026-07-07 | Gibson ChristopherFormer Director | 250K | $988K | 0.048% | 2026-07-07 | Fidelity Brokerage Services LLC |
| 2026-07-07 | Borgeson BlakeDirector | 40K | $159K | 0.008% | 2026-07-07 | Fidelity Brokerage Services LLC |
| 2026-07-06 | Gibson ChristopherFormer Director | 100K | $378K | 0.019% | 2026-07-06 | Fidelity Brokerage Services LLC |
| 2026-07-02 | Gibson ChristopherFormer Director | 100K | $375K | 0.019% | 2026-07-02 | Fidelity Brokerage Services LLC |
| 2026-07-01 | Gibson ChristopherFormer Director | 100K | $367K | 0.019% | 2026-07-01 | Fidelity Brokerage Services LLC |
| 2026-06-18 | Gibson ChristopherDirector | 300K | $962K | 0.057% | 2026-06-18 | Fidelity Brokerage Services LLC |
| 2026-06-18 | Gibson ChristopherDirector | 40K | $127K | 0.008% | 2026-06-18 | Fidelity Brokerage Services LLC |
| 2026-06-18 | Bumpus NamandjeDirector | 4K | $13K | 0.001% | 2026-06-18 | Fidelity Brokerage Services LLC |
| 2026-06-05 | Gibson ChristopherDirector | 40K | $145K | 0.008% | 2026-06-05 | Fidelity Brokerage Services LLC |
| 2026-06-03 | Bumpus NamandjeDirector | 4K | $16K | 0.001% | 2026-06-03 | Fidelity Brokerage Services LLC |
| 2026-06-02 | Borgeson BlakeDirector | 30K | $110K | 0.006% | 2026-06-02 | Fidelity Brokerage Services LLC |
| 2026-05-22 | Gibson ChristopherDirector | 40K | $123K | 0.008% | 2026-05-22 | Fidelity Brokerage Services LLC |
| 2026-05-07 | Gibson ChristopherDirector | 40K | $135K | 0.008% | 2026-05-07 | Fidelity Brokerage Services LLC |
| 2026-05-05 | Borgeson BlakeDirector | 30K | $106K | 0.006% | 2026-05-05 | Fidelity Brokerage Services LLC |
| 2026-04-22 | Gibson ChristopherDirector | 40K | $144K | 0.008% | 2026-04-22 | Fidelity Brokerage Services LLC |
| 2026-04-07 | Gibson ChristopherDirector | 40K | $124K | 0.008% | 2026-04-07 | Fidelity Brokerage Services LLC |
| 2026-04-07 | Borgeson BlakeDirector | 30K | $93K | 0.006% | 2026-04-07 | Fidelity Brokerage Services LLC |
| 2026-03-23 | Gibson ChristopherDirector | 40K | $130K | 0.008% | 2026-03-23 | Fidelity Brokerage Services LLC |
| 2026-03-17 | Taylor Ben ROfficer | 8K | $27K | 0.002% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-03-09 | Najat KhanOfficer | 28K | $95K | 0.005% | 2026-03-09 | Merrill Lynch |
| 2026-03-03 | Borgeson BlakeDirector | 170K | $588K | 0.033% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-02-19 | Gibson ChristopherDirector | 40K | $138K | 0.008% | 2026-02-19 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Taylor Ben ROfficer | 13K | $41K | 0.003% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-04 | Gibson ChristopherDirector | 40K | $165K | 0.008% | 2026-02-04 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of RXRX in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 8.5% of the class (44,541,605 shares), filed 2026-07-29 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 34.7M | 6.6% | 2026-06-30 |
| 2026-07-31 | 13G | Vanguard Portfolio Managementinvestment adviser | 31.4M | 6.0% | 2026-06-30 |
| 2026-07-31 | 13G | Vanguard Capital Managementinvestment adviser | 26.7M | 5.1% | 2026-06-30 |
| 2026-07-29 | 13G/Ano. 5 | BlackRock, Inc.parent holding company | 44.5M | 8.5% | 2026-06-30 |
| 2026-03-27 | 13G/Ano. 4 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-05 | 13G/Ano. 6 | BAILLIE GIFFORD & COinvestment adviser | 23.8M | 4.6% | 2025-12-31 |
| 2026-02-03 | 13G/Ano. 3 | ARK Investment Management LLCinvestment adviser | 37.3M | 7.3% | 2025-12-31 |
| 2026-02-03 | 13G/Ano. 3 | Catherine D. Woodparent holding company, individual | 37.3M | 7.3% | 2025-12-31 |
| 2025-12-23 | 13D/Ano. 3 | MDC Capital Partners (Ventures), LPpartnership | 7.1M | 1.4% | 2024-11-20 |
| 2025-12-23 | 13D/Ano. 3 | MDC Capital Partners (Ventures) GP, LPpartnership | 7.1M | 1.4% | 2024-11-20 |
| 2025-12-23 | 13D/Ano. 3 | MIC Capital Management UK LLPinvestment adviser | 2.6M | 0.5% | 2024-11-20 |
| 2025-12-23 | 13D/Ano. 3 | MC Alternative Solutions, LPpartnership | 1.4M | 0.3% | 2024-11-20 |
| 2025-12-23 | 13D/Ano. 3 | MIC Capital Partners (Ventures) Europe Parallel (Luxembourg) Aggregator SCSpother entity | 1.2M | 0.2% | 2024-11-20 |
| 2025-12-23 | 13D/Ano. 3 | Mubadala Investment Co PJSCcorporation | 0 | 0.0% | 2024-11-20 |
| 2025-12-23 | 13D/Ano. 3 | Mamoura Diversified Global Holding PJSCcorporation | 0 | 0.0% | 2024-11-20 |
13F holders
Tracked managers holding RXRX at their latest 13F. JSON7 of the 30 tracked managers held RXRX at their latest 13F, $173.0M in total at quarter-end prices. ARK Investment Management is the largest at $151.7M (1.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| ARK Investment Management | 2026-06-30 | 41.3M | $151.7M | 0.98% | +1.1M |
| Two Sigma Investments | 2026-06-30 | 3.4M | $12.3M | 0.01% | -713K |
| Millennium Management | 2026-06-30 | 1.8M | $6.7M | 0.00% | -778K |
| AQR Capital Management | 2026-06-30 | 422K | $1.5M | 0.00% | +178K |
| Citadel Advisors | 2026-06-30 | 128K | $472K | 0.00% | -496K |
| D. E. Shaw & Co. | 2026-06-30 | 38K | $139K | 0.00% | -8K |
| Bridgewater Associates | 2026-06-30 | 38K | $138K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Recursion Pharmaceuticals reported revenue of $7.7M, down 60.1% from the same quarter a year earlier, and net loss of $131.0M (-0.25 diluted EPS). In FY 2025 it generated -$371.8M of operating cash flow.
- Cash
- $545.7M
- Equity
- $915.0M
- Total assets
- $1.21B
- Shares outstanding
- 535,342,170
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $7.7M | -$131.0M | -1708.0% | -0.25 |
| Q1 FY 2026 | 2026-03-31 | $6.5M | -$117.5M | -1815.6% | -0.22 |
| Q4 FY 2025derived | 2025-12-31 | $35.5M | -$108.1M | -304.2% | n/a |
| Q3 FY 2025 | 2025-09-30 | $5.2M | -$162.3M | -3135.3% | -0.36 |
| Q2 FY 2025 | 2025-06-30 | $19.2M | -$171.9M | -894.2% | -0.41 |
| Q1 FY 2025 | 2025-03-31 | $14.7M | -$202.5M | -1373.3% | -0.50 |
| Q4 FY 2024derived | 2024-12-31 | $4.5M | -$178.9M | -3935.5% | n/a |
| Q3 FY 2024 | 2024-09-30 | $26.1M | -$95.8M | -367.5% | -0.34 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $74.7M | -$644.8M | -$371.8M | $6.5M | n/a | n/a |
| FY 2024 | 2024-12-31 | $58.8M | -$463.7M | -$359.2M | $13.7M | n/a | n/a |
| FY 2023 | 2023-12-31 | $44.6M | -$328.1M | -$287.8M | $12.0M | n/a | n/a |
| FY 2022 | 2022-12-31 | $39.8M | -$239.5M | -$83.5M | $37.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | $10.2M | -$186.5M | -$158.6M | $39.8M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Recursion Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Recursion Pharmaceuticals (RXRX), SEC CIK 1601830, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-06.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-15.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-06.JSON and CSV
- Company record
- EDGAR filing index for CIK 1601830Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of RXRX is sold short?
161,926,247 shares were held short at the 2026-10-15 settlement, 4.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is RXRX's daily short volume?
On 2026-10-28, 6,453,739 of the 14,078,419 RXRX shares reported to FINRA were sold short, 45.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does RXRX have fails to deliver?
The SEC's latest file shows 490,129 RXRX shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are RXRX insiders buying or selling?
Insiders at RXRX reported 5 open-market sells worth $644K in the last 90 days and no open-market buys. Latest filing: HERSHBERG ROBERT (Director) on 2026-10-06.
Have RXRX insiders filed to sell?
50 Form 144 notices on file for RXRX worth $13.4M at the prices reported; 13 in the last 90 days worth $2.9M. Latest: Borgeson Blake filed on 2026-10-06 to sell 50,000 shares ($242K) from 2026-10-06.
Who owns 5% or more of RXRX?
6 holders report 5% or more of RXRX in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 8.5% of the class (44,541,605 shares), filed 2026-07-29 for an event on 2026-06-30.
What did RXRX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Recursion Pharmaceuticals reported revenue of $7.7M, down 60.1% from the same quarter a year earlier, and net loss of $131.0M (-0.25 diluted EPS). In FY 2025 it generated -$371.8M of operating cash flow.
Which tracked 13F managers own RXRX?
7 of the 30 tracked 13F managers held RXRX shares at their latest filing, $173.0M in all. The largest: Cathie Wood's ARK Investment Management (41.3M shares, $151.7M), Two Sigma Investments (3.4M shares, $12.3M), Izzy Englander's Millennium Management (1.8M shares, $6.7M), Cliff Asness's AQR Capital Management (422K shares, $1.5M), Ken Griffin's Citadel Advisors (128K shares, $472K), D. E. Shaw & Co. (38K shares, $139K). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.